At the end of January, the small-cap biotechnology company AVEO Oncology (AVEO) updated investors on the delayed timeline for filing with FDA for their lead compound tivozanib. This news led to a … [Read more...] about Evaluating the Merits of AVEO’s Potential Purchase
Acquisitions in pharmaceutical industry staying at an elevated paceStrong balance sheet even before having any drugs approved for salePromising lentiviral genetic treatment platformSignificant … [Read more...] about Acquisition Targets: Could Bluebird Be In Season?
Introduction Bristol-Myers Squibb (NYSE: BMY) is a profitable global bio-pharmaceutical company targeting an array of serious diseases and unmet medical needs. Earlier this month BMY announced … [Read more...] about Bristol-Myers Squibb Positioned For Deep Penetration In the Multiple Myeloma Market
LEAVE A COMMENT AND CLICK HERE TO SUBSCRIBE FOR MS ARTICLE ALERTS AND OUR NEWSLETTER! Adma Biologics (Nasdaq: ADMA) announced today filing of supplementary information to the FDA in … [Read more...] about MS Monday Update-ADMA, CELG
Overview Galectin Therapeutics (NASDAQ GALT $5.96) is a leader in the development of a treatment for Non-Alcoholic SteatoHepatitis, an unmet medical need worth billions. Their star drug … [Read more...] about GALT is Primed for Acquisition or Partnership